PALO ALTO, Calif.--(BUSINESS WIRE)--Based on its recent analysis of the protein separation technologies market, Frost & Sullivan today announced that Pressure BioSciences, Inc. (NASDAQ:PBIO) (“PBI”) has been named the recipient of the 2007 North American Frost & Sullivan Award for Technology Innovation.
This Award recognizes Pressure BioSciences for its development of a new, cutting-edge sample preparation technology for tissue and cell disruption and for the development of a method for the detergent-free extraction of proteins from lipid rich tissues. This novel approach combines the power of the Company’s Pressure Cycling Technology (PCT) with the innovative chemistry of its ProteoSolve-LRS kit, resulting in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.
“Protein expression from lipid rich tissues is crucial to understanding many disease states such as obesity, heart disease, diabetes, and certain cancer types, among others,” says Frost & Sullivan Senior Research Analyst Sandhya Kamath. “As a result, sample preparation is drawing attention in proteomic studies since it can affect the accuracy and the overall quality of the downstream analytical processes.”
For instance, conventional detergent-based methods used to extract proteins from tissues produce highly variable results. This increases the processing time for protein extraction as well as the costs, compromising the quantity and quality of the extracted proteins.
Pressure BioSciences offers an automated method of protein extraction that allows for optimal protein recovery.
“Unlike conventional methods of tissue delipidation that comprise several stages such as cell and tissue disruption, protein extraction from lipids, and partitioning, the new PCT-dependent sample preparation approach from Pressure BioSciences combines these complex stages into a single step, as a result of which the fractions of proteins and lipids generated from each sample can be analyzed individually, faster, more efficiently, and with more reproducibility,” notes Kamath. “Moreover, this approach integrates PCT and reagents to extract and fractionate proteins from lipid-rich tissues in a detergent-free manner.”
Pressure BioSciences’ PCT technology can be applied across genomic and proteomic sample preparation, enzyme control, pathogen inactivation, immunodiagnostics, and protein purification.
To enhance the proof of concept, scientists at Pressure BioSciences collaborated with researchers at the Harvard School of Public Health to carry out a research study on the comparative proteomic analysis of adipose tissue isolated from genetically different animal lines.
The study exposed differences in protein expression that could be the base for newer research in mechanistic studies of obesity and Type 2 diabetes. The firm’s researchers are also working to widen the scope of pressure-driven liquid-liquid extraction in biological samples.
In recognition of Pressure BioSciences’ commendable innovation and the resulting technology advancement in the extraction and fractionation of proteins, Frost & Sullivan proudly presents it with the 2007 Award for Technology Innovation.
Each year, Frost & Sullivan presents this Award to the company that has demonstrated excellence in new products and technologies within their industry. The Award recognizes innovation through the launch of a broad line of emerging products and technologies.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling, platform technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, and protein purification.
Forward-Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the use of the PCT SPS by the Brooklyn Hospital Center and the NYU School of Medicine, the results of their studies having been presented at the Annual Scientific Meeting of the American College of Gastroenterology. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that other laboratories may be unable to duplicate the results generated by Dr. Momeni and her colleagues; the possibility that the data generated may not be beneficial in the development of new therapeutics and diagnostics for colon cancer; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
CONTACT:
Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Sr. Vice President of Finance & CFO
(508) 580-1818